Trial Profile

A First-in-Human (FIH), Open-Label, Phase 1 Study of ADG206, a CD137 Agonist Antibody, in Subjects With Advanced/Metastatic Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 19 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ADG 206 (Primary)
Indications Solid tumours
Focus Adverse reactions; First in man
Sponsors Adagene

Most Recent Events

14 Aug 2024 Planned End Date changed from 1 Dec 2024 to 1 Oct 2025.
14 Aug 2024 Planned primary completion date changed from 1 Apr 2024 to 1 May 2025.
25 Jul 2024 According to an Adagene media release, the company has now enrolled 13 patients in the trial and dose escalation continues with a cohort ongoing at 6 mg/kg Q3W.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com